Cardiac tamponade caused by carcinomatous pericarditisis a complication of advanced malignancy. Management of cardiac tamponade is sometimes difficult, and sudden death if it is not controlled properly (1). Lung cancer is one of the most important causes ofthis oncology emergency (2). We show herein a small cell lung cancer (SCLC) patient with cardiac tamponade, who had a long-term survival.
To the Editor, Cardiac tamponade caused by carcinomatous pericarditisis a complication of advanced malignancy. Management of cardiac tamponade is sometimes difficult, and sudden death if it is not controlled properly (1) . Lung cancer is one of the most important causes ofthis oncology emergency (2) . We show herein a small cell lung cancer (SCLC) patient with cardiac tamponade, who had a long-term survival.
A 71-year-old male was referred to our hospital following a three-month history of hoarseness. Upon admission, the serum levels of neuron-specific enolase were elevated to 156.7 ng/mL. Chest radiograph and CT scan revealed an ill-defined mass in the upper lobe of the right lung, with ipsilateral mediastinal lymph node swelling and pericardial fluid. The pathological examination of the tumor, which was obtained by fiberoptic bronchoscopy, was consistent with a diagnosis of SCLC. Systemic evaluation revealed no distant metastasis. The patient received 3 courses of carboplatin (AUC= 5, day 1, q28) plus etoposide (100 mg/m 2 , day 1-3, q28). Soon after 3 courses of the chemotherapy, however, the patient complained dyspnea and tachycardia. Physical examination revealed distended jugular veins, paradoxical pulse, and hypotension. Chest CT scan showed acutely increase of pericardial fluid despite of shrinkage of the primary lesion and mediastinal lymph nodes (Figure 1 showed low voltage and ventricular diastolic dysfunction in echo cardiogram. With the diagnosis of cardiac tamponadecaused by carcinomatous pericarditis, pericardiocentesis was immediately performed to control cardiac tamponade. Cytological specimens were obtained from the fluid and they were proven to be SCLC cells. As the patient had good performance status (ECOG PS 1), the patient received weekly amrubicin (one of the anthracycline analogues, 35 mg/m 2 , day 1,8, 15) and responded well for 12 months (3). Neither severe hematological nor non-hematological adverse events were observed. No additional therapy for local control of carcinomatous pericarditis was required. As followup chest CT scan revealed recurrence at the site of the primary lesion, the patient received CPT-11 (100 mg/m 2 , day 1, q28) for 10 months and carboplatin (AUC= 5, day 1, q28)plus etoposide (100 mg/m 2 , day 1-3, q28) for 3 months. The patient died of SCLC 30 months after the diagnosis of the disease.
Pericardiocentesis is the emergency procedure for patients with cardiac tamponade and it must be indicated for either good or poor conditioned patients with this condition (4) . Complications related to this procedure are considered to be high in poor conditioned and elderly patients. Good PS in limited disease SCLC, maintenance of PS even acutely development of cardiac tamponade were the favorable factorsin our patient. Successful control of cardiac tamponade by pericardiocentesis must be another favorable factor. In addition to them, good response to the second-and later-lines of chemotherapy was also favorable factor in our patient. These several favorable factors must have relationship with a long-term survival. Even development of cardiac tamponade in SCLC patients, a long-term survival would be achieved if there might be several favorable factors as observed in our patient.
